Cohort | Performance parameters | |||||
Number of cancer samples | Number of control samples | Specificity % | Sensitivity % | Cancer rate % | DLRp | |
Optimisation | 235 | 266 | 90.6 (87.1 - 94.1) | 41.3 (35.0 - 47.6) | - | 4.4 (2.9 - 6.6) |
Audit | 19 | 817 | 90.5 (88.4 - 92.5) | 47.4 (24.9 - 69.8) | 2.3 | 5.0 (3.0 - 8.3) |
Nodulec (4 - 20 mm) | 15 | 87 | 83.9 (76.2 - 91.6) | 40.0 (15.2-64.8) | 14.7 | 2.5 (1.1 - 5.4) |
Nodulec (>20 mm) | 22 | 24 | 91.7 (80.6 - 100) | 36.4 (16.3 - 56.5) | 47.8 | 4.4 (1.0 - 18.4) |
Nodule | 37 | 111 | 85.6 (79.1 - 92.1) | 37.8 (22.2 - 53.5) | 22.3 | 2.6 (1.4 - 4.8) |